Deverra Therapeutics

Deverra Therapeutics

Growth Stage

Seeking Remission For All

Seeking Remission For All

Overview

Raised to Date: Raised: $496,218

Total Commitments ($USD)

Platform

StartEngine

Start Date

03/27/2024

Close Date

04/29/2024

Min. Goal
$15,000
Max. Goal
$1,235,000
Min. Investment

$500

Security Type

Equity - Common

SEC Filing Type

RegCF    Open SEC Filing

Price Per Share

$2.09

Pre-Money Valuation

$59,837,329

Rolling Commitments ($USD)

Status

Active

Reporting Date

04/16/2024

Days Remaining

11

% of Min. Goal

3,308%

% of Max. Goal

40%

Likelihood of Max
unlikely
Avg. Daily Raise

$24,811

# of Investors

167

Momentum
hot.svg
Create a free account today to gain access to KingsCrowd analytics.
Year Founded

2020

Industry

Healthcare & Pharmaceuticals

Tech Sector

Biotech

Location

Seattle, Washington

Deverra Therapeutics, with a valuation of $59.84 million, is raising funds on StartEngine. It is a clinical-stage biotech company that provides universal donor treatments for accessible immune cell therapies. Deverra Therapeutics’ immune cell therapies are affordable, safe, and readily available to reinvent the way therapies are delivered for cancer and other life-threatening illnesses. The company’s lead clinical asset, Dilanubicel, has shown significant remission rates in a phase 2 leukemia clinical trial with 184 patient infusions. Michael Yurkowsky and Colleen Delaney founded Deverra Therapeutics in September 2020. The current crowdfunding campaign has a minimum target of $14,999.93 and a maximum target of $1.23 million. The campaign proceeds will be used for research and clinical development.

Summary Profit and Loss Statement

FY 2022 FY 2021

Revenue

$0

$0

COGS

$6,678,838

$8,599,659

Tax

$0

$0

 

 

Net Income

$-6,899,704

$-9,035,503

Summary Balance Sheet

FY 2022 FY 2021

Cash

$78,636

$1,795,952

Accounts Receivable

$0

$0

Total Assets

$327,030

$4,845,249

Short-Term Debt

$7,448,108

$2,684,474

Long-Term Debt

$256,667

$926,203

Total Liabilities

$7,704,775

$3,610,677

Financials as of: 03/27/2024
Create a free account today to gain access to KingsCrowd analytics.

Upgrade to gain access

Pay Monthly
Annually (Save 17%)

Edge

$25 /month
billed annually
Free portfolio tracking, data-driven ratings, AI analysis and reports
Plan Includes:
Everything in Free, plus
Company specific KingsCrowd ratings and analyst reports
Deal explorer and side-by-side comparison
Startup exit and failure tracking
Startup market filters and historical industry data
Advanced company search ( with ratings)
Get Edge Annual
Already a member? Log in here.
Founders: enhance your startup's credibility on KingsCrowd. Create an account to claim this raise page.
Add to portfolio
Deverra Therapeutics on StartEngine 2024
Platform: StartEngine
Security Type: Equity - Common
Valuation: $59,837,329
Price per Share: $2.09

Follow company

Follow Deverra Therapeutics on StartEngine 2024

Buy Deverra Therapeutics's Deal Report

Deverra Therapeutics Deal Report

Get KingsCrowd’s comprehensive report on Deverra Therapeutics including:

  • How our proprietary algorithm rates their current capital raise (1-5 stars)
  • Detailed price, market, team, differentiators, performance, and risk ratings
  • Whether Deverra Therapeutics is undervalued or overvalued
  • Scores on the founding team and key personnel's background and expertise

Buy the Deverra Therapeutics deal report for only $10!

Email address:
Looking to buy more than one deal report? Get unlimited reports by upgrading to Edge